277 related articles for article (PubMed ID: 35995347)
21. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
Hisatome I; Li P; Miake J; Taufiq F; Mahati E; Maharani N; Utami SB; Kuwabara M; Bahrudin U; Ninomiya H
Circ J; 2021 Jan; 85(2):130-138. PubMed ID: 33342914
[TBL] [Abstract][Full Text] [Related]
22. Xanthine oxidoreductase inhibition ameliorates high glucose-induced glomerular endothelial injury by activating AMPK through the purine salvage pathway.
Yang KJ; Park H; Chang YK; Park CW; Kim SY; Hong YA
Sci Rep; 2024 May; 14(1):11167. PubMed ID: 38750091
[TBL] [Abstract][Full Text] [Related]
23. Dispelling dogma and misconceptions regarding the most pharmacologically targetable source of reactive species in inflammatory disease, xanthine oxidoreductase.
Kelley EE
Arch Toxicol; 2015 Aug; 89(8):1193-207. PubMed ID: 25995007
[TBL] [Abstract][Full Text] [Related]
24. Plasma Xanthine Oxidoreductase Activity Associated with Glycemic Control in Patients with Pre-Dialysis Chronic Kidney Disease.
Nakatani S; Ishimura E; Murase T; Nakamura T; Nakatani A; Toi N; Nishide K; Uedono H; Tsuda A; Kurajoh M; Yamada S; Mori K; Inaba M; Emoto M
Kidney Blood Press Res; 2021; 46(4):475-483. PubMed ID: 34082427
[TBL] [Abstract][Full Text] [Related]
25. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.
Bove M; Cicero AF; Veronesi M; Borghi C
Vasc Health Risk Manag; 2017; 13():23-28. PubMed ID: 28223818
[TBL] [Abstract][Full Text] [Related]
26. Xanthine oxidoreductase: a journey from purine metabolism to cardiovascular excitation-contraction coupling.
Agarwal A; Banerjee A; Banerjee UC
Crit Rev Biotechnol; 2011 Sep; 31(3):264-80. PubMed ID: 21774633
[TBL] [Abstract][Full Text] [Related]
27. Omeprazole impairs vascular redox biology and causes xanthine oxidoreductase-mediated endothelial dysfunction.
Pinheiro LC; Oliveira-Paula GH; Portella RL; Guimarães DA; de Angelis CD; Tanus-Santos JE
Redox Biol; 2016 Oct; 9():134-143. PubMed ID: 27521759
[TBL] [Abstract][Full Text] [Related]
28. Xanthine Oxidoreductase Inhibitors.
Vickneson K; George J
Handb Exp Pharmacol; 2021; 264():205-228. PubMed ID: 32789757
[TBL] [Abstract][Full Text] [Related]
29. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.
Berry CE; Hare JM
J Physiol; 2004 Mar; 555(Pt 3):589-606. PubMed ID: 14694147
[TBL] [Abstract][Full Text] [Related]
30. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Hu AM; Brown JN
Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular significance of adipose-derived adiponectin and liver-derived xanthine oxidoreductase in metabolic syndrome.
Fujishima Y; Kita S; Nishizawa H; Maeda N; Shimomura I
Endocr J; 2023 Jul; 70(7):663-675. PubMed ID: 37316258
[TBL] [Abstract][Full Text] [Related]
32. Allopurinol, an inhibitor of uric acid synthesis--can it be used for the treatment of metabolic syndrome and related disorders?
Suzuki I; Yamauchi T; Onuma M; Nozaki S
Drugs Today (Barc); 2009 May; 45(5):363-78. PubMed ID: 19584965
[TBL] [Abstract][Full Text] [Related]
33. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Puddu P; Puddu GM; Cravero E; Vizioli L; Muscari A
J Cardiol; 2012 May; 59(3):235-42. PubMed ID: 22398104
[TBL] [Abstract][Full Text] [Related]
34. Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis.
Peleli M; Zollbrecht C; Montenegro MF; Hezel M; Zhong J; Persson EG; Holmdahl R; Weitzberg E; Lundberg JO; Carlström M
Free Radic Biol Med; 2016 Oct; 99():472-484. PubMed ID: 27609225
[TBL] [Abstract][Full Text] [Related]
35. The effects of topiroxostat on vascular function in patients with hyperuricemia.
Higa S; Shima D; Tomitani N; Fujimoto Y; Kario K
J Clin Hypertens (Greenwich); 2019 Nov; 21(11):1713-1720. PubMed ID: 31556223
[TBL] [Abstract][Full Text] [Related]
36. [The uric acid cardio-nephropathy].
Viazzi F; Bonino B; Cappadona F; Pontremoli R
G Ital Nefrol; 2017 Mar; 34(Suppl 69):41-48. PubMed ID: 28682028
[TBL] [Abstract][Full Text] [Related]
37. Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout.
Nishino T; Okamoto K
J Biol Inorg Chem; 2015 Mar; 20(2):195-207. PubMed ID: 25501928
[TBL] [Abstract][Full Text] [Related]
38. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
[TBL] [Abstract][Full Text] [Related]
39. Xanthine Oxidoreductase-Derived Reactive Species: Physiological and Pathological Effects.
Battelli MG; Polito L; Bortolotti M; Bolognesi A
Oxid Med Cell Longev; 2016; 2016():3527579. PubMed ID: 26823950
[TBL] [Abstract][Full Text] [Related]
40. Effects of topiroxostat in hyperuricemic patients with chronic kidney disease.
Horino T; Hatakeyama Y; Ichii O; Matsumoto T; Shimamura Y; Inoue K; Terada Y; Okuhara Y
Clin Exp Nephrol; 2018 Apr; 22(2):337-345. PubMed ID: 28752287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
